Research Study to Improve Treatment Outcomes for Prescription Pain Killer Users

The goal of this Center for Addiction Research study is to improve treatment outcomes with buprenorphine-assisted detoxification from prescription pain relievers like Dilaudid, hydrocodone, oxycodone and methadone. The study initially involves the use of the drug buprenorphine, which is used to taper participants off prescription pain relievers, and gabapentin, known clinically as Neurontin. After being tapered off buprenorphine, participants receive Vivitrol, an FDA-approved drug shown to help prevent relapse in individuals who stop heroin or prescription pain reliever use. Study participants will meet with a research therapist weekly for an hour-long session that will include education and support, medication management, techniques to enhance motivation for abstinence and review of problem areas. There is no cost to participate in this study, and research subjects who are found eligible will receive monetary compensation for their time.

Eligibility Criteria:

  • Male or female
  • Ages 18-65
  • Problem with prescription pain killers
  • Able to attend clinic six days per week for the first three weeks

This study is no longer accepting participants.